Posted by Michael Wonder on 17 Jul 2026
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
17 July 2026 - Camurus today announced that the US FDA has accepted for review the resubmission of the new drug application for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly.
The FDA has assigned a PDUFA target action date of 18 December 2026.
